Literature DB >> 1711001

Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C.

K Chayama1, S Saitoh, Y Arase, K Ikeda, T Matsumoto, Y Sakai, M Kobayashi, M Unakami, T Morinaga, H Kumada.   

Abstract

Hepatitis C virus RNA as detected by reverse transcription and nested polymerase chain reaction was monitored in 16 patients with chronic hepatitis C treated with interferon. Hepatitis C virus RNA became undetectable after 4 to 8 wk of interferon administration in 13 of the 16 patients. During 6 mo of follow-up, 5 of the 13 patients who became negative for hepatitis C virus RNA after interferon administration remained negative, and all five continued to have normal ALT levels. Repeat liver biopsy in these five patients revealed histological improvement. Antibody to hepatitis C virus, which was initially positive in all treated patients, fell to undetectable levels in three of the five patients. In contrast, aminotransferase levels rose again in all eight patients who had become hepatitis C virus RNA negative but had again exhibited hepatitis C virus RNA after completion of therapy. In 16 untreated patients, hepatitis C virus RNA remained detectable. These results indicate that detection of hepatitis C virus RNA may be useful as a marker of viral replication in chronic hepatitis C; they also suggest that interferon should again be administered to patients who become hepatitis C virus RNA negative on treatment but again exhibit this marker of viral replication when treatment is stopped.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711001

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  22 in total

1.  Various S-GOT/S-GPT ratios in nonviral liver disorders and related physical conditions and life-style.

Authors:  Masako Mukai; Kotaro Ozasa; Kyohei Hayashi; Keiichi Kawai
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

2.  Management of chronic hepatitis C and prevention of hepatocellular carcinoma.

Authors:  Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

3.  Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study.

Authors:  E Villa; P Trande; A Grottola; P Buttafoco; A M Rebecchi; T Stroffolini; F Callea; A Merighi; L Camellini; P Zoboli; R Cosenza; L Miglioli; P Loria; R Iori; N Carulli; F Manenti
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

4.  Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection.

Authors:  Kiminori Uka; Fumitaka Suzuki; Norio Akuta; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

5.  Low-dose interferon in chronic hepatitis non-A/non-B: effects on quantitative liver function and structure in a randomized, controlled multicenter trial.

Authors:  J Reichen; M Solioz; H Bühler; J J Gonvers; M Knoblauch; D Lavanchy; P J Malé; B Meyer; M Schmid; L Bianchi
Journal:  Clin Investig       Date:  1993-11

6.  Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.

Authors:  Soocheol Jeong; Hiroshi Aikata; Yoshio Katamura; Takahiro Azakami; Tomokazu Kawaoka; Hiromi Saneto; Kiminori Uka; Nami Mori; Shintaro Takaki; Hideaki Kodama; Koji Waki; Michio Imamura; Hiroo Shirakawa; Yoshiiku Kawakami; Shoichi Takahashi; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

7.  Interferon treatment of chronic hepatitis C in patients with hemophilia or von Willebrand's disease in Japan.

Authors:  M Yoshikawa; H Fukui; H Kojima; H Yoshiji; T Sakamoto; H Imazu; T Nakanani; Y Matsumura; S Kuriyama; J Yamao
Journal:  J Gastroenterol       Date:  1995-06       Impact factor: 7.527

8.  Detection of hepatitis C virus RNA by a combined reverse transcription PCR assay: comparison with nested amplification and antibody testing.

Authors:  K K Young; J J Archer; O Yokosuka; M Omata; R M Resnick
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

Review 9.  Viral markers in the treatment of hepatitis B and C.

Authors:  H Schmilovitz-Weiss; M Levy; N Thompson; G Dusheiko
Journal:  Gut       Date:  1993       Impact factor: 23.059

10.  Storage conditions of blood samples and primer selection affect the yield of cDNA polymerase chain reaction products of hepatitis C virus.

Authors:  H T Cuypers; D Bresters; I N Winkel; H W Reesink; A J Weiner; M Houghton; C L van der Poel; P N Lelie
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.